Adamas Pharmaceuticals, which develops treatments for CNS disorders such as Parkinson's and Alzheimer's, announced terms for its IPO on Wednesday. The Emeryville, CA-based company plans to raise $51 million by offering 3.0 million shares at a price range of $16 to $18. At the midpoint of the proposed range, it would command a fully diluted market value of $352 million.
Adamas Pharmaceuticals, which was founded in 2000 and booked $71 million in sales for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol ADMS. Adamas initially filed confidentially on January 31, 2014. Credit Suisse and Piper Jaffray are the joint bookrunners on the deal.
